


THE EFFECTOR FUNCTIONS OF ANTIBODIES

Catherine Fridman
BMC423 2008


TWO CLASSES OF PATHOGENS

EXTRACELLULAR



BACTERIA:
Streptococcus, Staphylococcus,
Neisseria, Salmonella
PARASITES
Plasmodium, Trypanosoma,
Toxoplasma

INTRACELLULAR



VESICULAR BACTERIA:
Mycobacteria, Chlamydia,
Shigella, Legionella
PARASITES:
Leishmania, Schistosoma

CYTOSOLIC VIRUSES

HUMORAL IMMUNITY AND CELLULAR IMMUNITY

HUMORAL IMMUNITY (ANTIBODIES AND COMPLEMENT) IS USED TO FIGHT AGAINST EXTRACELLULAR BACTERIA

CELLULAR IMMUNITY IS USED TO FIGHT AGAINST INTRACELLULAR MICROBES (CTL/VIRUSES; TH/INTRACELLULAR BACTERIA)



Emil von Behring, Nobel prize of physiology or medicine in 1901

He discovered that the sera from animals vaccinated with « attenuated » diphtheria contained substances, antibodies that protected other animals from living organisms

The first successful treatment of a child occurred in 1891

Université Pierre et Marie Curie, Immunologie fondamentale

THE EFFECTOR FUNCTIONS OF ANTIBODIES

I-Antibodies, definitions, structure and isotypes

II-Effector functions of antibodies

1-Complement activation

2-FcR dependent functions :

-via the Fc gamma R :

Internalization

cytotoxicity


cell activation

inhibition of cell activation



-via the Fc epsilon R

III-Transport function via FcRn and PolyIgR

ANTIBODIES ARE BIFUNCTIONNAL MOLECULES



Immunology, 7th edition, D.Male et al., Mosby, Elsevier









TABLE 4-3 Chain composition of the five immunoglobulin classes in humans				
Class	Heavy chain	Subclasses	Light chain	Molecular formula
IgG	γ	$\gamma 1, \gamma 2, \gamma 3, \gamma 4$	κ or λ	$\gamma_2\kappa_2$ $\gamma_2\lambda_2$
IgM	μ	None	κ or λ	$(\mu_2\kappa_2)_n$ $(\mu_2\lambda_2)_n$ $n = 1 \text{ or } 5$
IgA	α	$\alpha 1, \alpha 2$	κ or λ	$(\alpha_2\kappa_2)_n$ $(\alpha_2\lambda_2)_n$ $n = 1, 2, 3, \text{ or } 4$
IgE	ϵ	None	κ or λ	$\epsilon_2\kappa_2$ $\epsilon_2\lambda_2$
IgD	δ	None	κ or λ	$\delta_2\kappa_2$ $\delta_2\lambda_2$

*See Figure 4-1 for general structures of five antibody classes.



Table 4-3
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W.H. Freeman and Company






IMMUNOGLOBULINS A

- PRESENT IN MUCOSAL TISSUES
- TWO ISOTYPES IgA1 et IgA2
- MONOMERS IN BLOOD ($\text{IgA1/IgA2} = 4$)
- DIMERS IN MUCUS ($\text{IgA1/IgA2} = 3:2$)




Université Pierre et Marie Curie, Immunologie fondamentale

Isotype of antibody	Subtypes	H chain	Serum concentr (mg/mL)	Serum half-life (days)	Secreted form	Functions
IgA	IgA1,2	α (1 or 2)	3.5	6	Monomer, dimer, trimer 	Mucosal immunity, neonatal passive immunity
IgD	None	δ	Trace	3	None	Naive B cell antigen receptor
IgE	None	ϵ	0.05	2	Monomer 	Mast cell activation (immediate hypersensitivity)
IgG	IgG1-4	γ (1,2,3 or 4)	13.5	23	Monomer 	Opsonization, complement activation, antibody-dependent cell-mediated cytotoxicity, neonatal immunity, feedback inhibition of B cells
IgM	None	μ	1.5	5	Pentamer 	Naive B cell antigen receptor, complement activation

Basic Immunology, 2nd edition, Abbas and Lichtman, Saunders Elsevier ed

Ig isotypes have an heterogeneous distribution in the body



Immunobiology, 6th edition, C. Janeway et al., Churchill, Livingstone

Isotypes have different functional activities

Function: activity	IgM	IgD	IgG1	IgG2	IgG3	IgG4	IgA	IgE
Neutralization	+	-	++	++	++	++	++	-
Opsonization	+	-	++	++	++	++	++	-
Sensitization for killing by NK cells	-	-	++	++	++	++	++	-
Sensitization of mast cells	-	-	+	+	+	+	+	++
Activates complement system	+++	-	++	+	++	+	+	-
Distribution	IgM	IgD	IgG1	IgG2	IgG3	IgG4	IgA	IgE
Transport across epithelium	+	-	-	-	-	-	++	-
Transport across placenta	-	-	++	+	++	+	-	-
Diffusion into extravascular sites	+	-	++	++	++	++	++	+
Mean serum level (mg mL ⁻¹)	1.5	0.04	9	3	1	0.5	2.1	3x10 ⁻¹

Immunobiology, 6th edition, C. Janeway et al., Churchill, Livingstone





FUNCTIONS OF ANTIBODIES

IgM PRESENT IN BODY FLUIDS
DEFENSES AGAINST INFECTION AND CANCER

IgG PRESENT IN BODY FLUIDS AND TISSUES,
DEFENSES AGAINST INFECTION AND CANCER

IgA PRESENT IN MUCOSAL SURFACES,
NEUTRALIZATION OF PATHOGENS

IgE PRESENT IN TISSUES AND ON VASCULAR ENDOTHELIUM,
ALLERGY, DEFENSES AGAINST HELMINTHS






ANTIBODIES



C1

C4b

C4a

(from Janeway et al, « Immunobiology », 5th edition Garland ed »)











OTHER FUNCTIONS OF ANTIBODIES		
CLASS	FcR TYPE	FcR for TRANSPORT OF Ig
IgM	-	PolyIgR
IgG	RFcγ	RFcn
IgA	RFcα	PolyIgR
IgE	RFcε	-
IgD	-	-


BIOLOGICAL ACTIVITIES OF Ag-Ab (IgG) COMPLEXES

- **Internalization**
 - Phagocytosis
 - Endocytosis
- **Cell activation :**
 - Release of mediators
 - Perforin and granzyme release (ADCC)
 - Cytokine secretion
- **Inhibition of Cell activation**





MICE DEFICIENT IN	HYPERSENSITIVITY REACTIONS (II,III) ARTHUS REACTION	AUTOIMMUNE DISEASES (IgG DEPENDENT)
ACTIVATING FcγR	IMPAIRED	RESISTANT
INHIBITORY FcγR	ENHANCED	INCREASED SUSCEPTIBILITY





Université Pierre et Marie Curie, Immunologie fondamentale


FcγR POLYMORPHISMS IN HUMAN AUTOIMMUNE DISEASES

INCREASED SUSCEPTIBILITY TO	FcγRIIa	FcγRIIB	FcγRIIIA	FcγRIIIB
SYSTEMIC LUPUS	131 Arg			
ERYTHEMATOSUS (SLE)		232 Thr* and promoter	158 Phe	
			NA2	
RHEUMATOID ARTHRITIS (RA)			158 Phe	
WEGENER GRANULOMATOSIS				NA1
GUILLAIN BARRE SYNDROME	131Arg			NA2
MULTIPLE SCLEROSIS	131 Arg			NA2

Fcγ RECEPTORS CONTROL ANTIBODY THERAPY TO METASTATIC MELANOMA



Cartron et al., Blood 2002



EFFECTOR FUNCTIONS OF IgE

FcεRI: High-affinity IgE receptor




Figure 15-4a
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W.H. Freeman and Company

Allergen cross-linkage of cell-bound IgE




Figure 15-5a
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W.H. Freeman and Company




Figure 15-6
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W.H. Freeman and Company






TABLE 15-3 Principal mediators involved in type I hypersensitivity

Mediator	Effects
PRIMARY	
Histamine, heparin	Increased vascular permeability; smooth muscle contraction
Serotonin (rodents)	Increased vascular permeability; smooth muscle contraction
Eosinophil chemotactic factor (ECF-A)	Eosinophil chemotaxis
Neutrophil chemotactic factor (NCF-A)	Neutrophil chemotaxis
Proteases (trypsin, chymase)	Bronchial mucus secretion; degradation of blood vessel basement membrane; generation of complement split products
SECONDARY	
Platelet-activating factor	Platelet aggregation and degranulation; contraction of pulmonary smooth muscles
Leukotrienes (slow reactive substance of anaphylaxis, SRS-A)	Increased vascular permeability; contraction of pulmonary smooth muscles
Prostaglandins	Vasodilation; contraction of pulmonary smooth muscles; platelet aggregation
Bradykinin	Increased vascular permeability; smooth muscle contraction
Cytokines	
IL-1 and TNF- α	Systemic anaphylaxis; increased expression of CAMs on venular endothelial cells
IL-4 and IL-13	Increased IgE production
IL-3, IL-5, IL-6, IL-10, TGF- β , and GM-CSF	Various effects (see Table 12-1)

Table 15-3
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W.H. Freeman and Company



TRANSPORT FUNCTIONS OF ANTIBODIES

Formation of secretory IgA





Figure 4-19b
Kuby IMMUNOLOGY, Sixth Edition
© 2007 W.H. Freeman and Company

Immunoglobulins in the serum of the fetus and newborn child



Transport across Placenta

Immunobiology, 6th edition, C. Janeway et al., Churchill, Livingstone